• OPEN AN ACCOUNT
Indian Indices
Nifty
24,870.10 -213.65
(-0.85%)
Sensex
81,306.85 -693.86
( -0.85%)
Bank Nifty
55,149.40 -606.05
( -1.09%)
Nifty IT
35,440.85 -283.05
( -0.79%)
Global Indices
Nasdaq
45,658.64 852.13
(1.90%)
Dow Jones
6,488.44 97.27
(1.52%)
Hang Seng
42,587.47 -22.70
(-0.05%)
Nikkei 225
9,321.40 12.20
(0.13%)
Forex
USD-INR
87.17 0.12
(0.14%)
EUR-INR
101.39 0.01
(0.01%)
GBP-INR
117.16 -0.12
(-0.11%)
JPY-INR
0.59 0.00
(-0.18%)

EQUITY - MARKET SCREENER

Enfuse Solutions Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
92697
INE0S3X01014
39.6012478
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ENFUSE
67.37
218.76
EPS(TTM)
Face Value()
Div & Yield %
3.67
10
0
 

mold tek packaging ltd
Glenmark USA to launch Micafungin for Injection 50 mg/vial and 100 mg/vial
Aug 19,2025

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial).

Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine®2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA – 021506 and the company will begin distribution in September 2025.

According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million*.